MEDWIN PUBLISHERS
Committed to Create Value for Researchers

Virology & Immunology Journal
ISSN: 2577-4379

Strategies to Combat Japanese Encephalitis

Bhange K[1] and Singh N[2]*

[1]Department of Biochemistry, Pandit Jawahar Lal Nehru Memorial Medical College, India

[2]Virology Lab, Department of Microbiology, Pandit Jawahar Lal Nehru Memorial Medical College, India

***Corresponding author:** Neha Singh, Department of Microbiology, Pandit Jawahar Lal Nehru Memorial Medical College, India, Email: nehaashishsingh2015@gmail.com

Mini Review

Volume 7 Issue 3

Received Date: September 13, 2023

Published Date: September 26, 2023

DOI: 10.23880/vij-16000328

Abstract

Japanese encephalitis (JE) is still one of the most dangerous mosquito-transmitted infections in the world, and there is no cure or set of rules for treating it. The clinical signs and progression of the infection are influenced by the pathogenicity of both the viral determinants and the host immune responses. JE can affect both fine and gross motor skills, making it difficult to perform tasks including walking, gripping, and coordinating actions. In the absence of antiviral treatment, vaccination is the only way to produce long-lasting protection against JEV infection. The disease still lacks a cure or treatment recommendations. Various global institutes such as WHO, Gavi, UNICEF etc support the JE elimination strategies along with governments of various nations. Improvements and developments were being made in the fields of Japanese encephalitis (JE) research, prevention, and treatment.

Introduction

Japanese encephalitis (JE) is a mosquito-transmitted acute infection of the central nervous system brought on by the Japanese encephalitis virus (JEV) [1]. Fever, headache, and convulsions are the typical general symptoms seen in JE patients. The JE virus which belongs to family flaviviridae consists of spherical particles that are 50 nm in size and have an electron-dense core that is 30 nm in diameter. Positive-sense single-stranded RNA with a length of about 11 kb makes up the genome. The JEV capsid shares a similar protein fold with the capsid proteins of the dengue virus (DENV), the Zika virus (ZIKV) and the West Nile virus (WNV). It shows a helical secondary structure (helixes 1-4) [2]. Five JEV genotypes, ranging from G-I to G-V, were discovered by nucleotide sequencing research of the JEV genome [3,4]. The Japanese encephalitis (JE) is one of the most significant endemic encephalopathies in the globe, particularly in Eastern and Southeastern Asia specifically in nations like Japan, China, India, and Southeast Asian countries, the virus is most prevalent in rural and agricultural areas of Asia [1,5,6]. Clinically, acute encephalitis syndrome (AES) instances are difficult to identify from other encephalitis cases, proper testing for JE or related viruses test confirmation is required in these situations [3,7,8]. Although there is no particular antiviral therapy for JE, research is still being done on prospective medicines and strategies to control the disease's symptoms and side effects. The outcomes for severe patients are getting better thanks to developments in critical care and supportive therapies. In order to more reliably predict JE outbreaks, high-risk locations have been identified and epidemiological and surveillance advancements have been made. Planning vaccine campaigns and mosquito control initiatives can benefit from this information.

Disease Manifestation

Both the viral determinants' and the host's immune responses' pathogenicity affect the clinical manifestations and course of the infection [9]. Japanese encephalitis (JE), particularly in those who have had severe episodes of the illness, can have serious long-term repercussions. Each person will experience these effects differently, and not everyone who acquires JE will inevitably develop long-term complications. Clinical complaints and recent visit locations should be confirmed by doctors. A cranial CT or MRI of the brain would be performed if a patient traveled to an area where JE is endemic to look for any abnormalities [10]. The disease could be diagnose by estimating JE-specific IgM antibodies through ELISA in serum and cerebro spinal fluid [11-13]. Reverse transcriptase Polymerase Chain Reaction (RT-PCR) is also used to confirm the presence of JE virus in the body [14]. Neurological impairments can affect many survivors of severe JE. These deficiencies may show up as issues with coordination, motor function, and muscle weakness. Some people may develop temporary or permanent paralysis in different body areas. JE can occasionally lead to communication problems, such as speech and language deficits. It may be difficult for people as a result to successfully express themselves and interact with others. Moreover, JE can cause cognitive dysfunction, such as memory issues, focus and concentration issues, and learning deficits [15]. These cognitive deficiencies may necessitate continuing rehabilitation and support because they might considerably affect a person's capacity to carry out daily responsibilities. Furthermore, some people with JE may experience changes in their behavior or personalities. Irritability, mood swings, anger, and emotional instability are a few examples of these changes. Both affected person and their caretakers may find these behavioral changes problematic. Additionally, severe JE can make it more likely for people to develop epilepsy or have recurring seizures. An individual's daily life can be further disrupted by epileptic seizures, which call for continual treatment with antiepileptic drugs. JE may also lead to hearing loss and visual problems. These problems could vary from minor to severe, and they might need to be treated with therapy or assistive technology. JE can impair both fine and gross motor abilities, making activities like walking, gripping, and coordinating motions challenging. For the purpose of enhancing motor abilities and regaining functional independence, physical therapy may be required. The virus can cause growth and developmental deficits in kids who contract JE. They may need specific care and intervention because this may affect their physical and cognitive development. In terms of schooling, career, and social connections, JE's long-term impacts can pose serious obstacles. To lead fulfilling lives, affected people and their families may need support and accommodations. It's crucial to remember that not everyone who develops Japanese encephalitis will experience these consequences, and that the intensity and kind of long-term repercussions might vary greatly among the individuals. The prognosis for people with JE can be improved with early diagnosis and adequate medical care, including therapy and rehabilitation. A crucial preventive measure to lower the chance of developing this potentially fatal illness is vaccination.

Preventive Strategies

A strong humoral immune response and cytokines released by cell-mediated immunity during JEV infections are essential for controlling the spread of the infection [9]. Immunization is the sole method to create long-term, durable protection against JEV infection in the absence of antiviral intervention. The G3 JE virus (JEV) used in the current Japanese encephalitis (JE) vaccine can produce a protective response against JEV genotypes G1–G4 [16]. Depending on the type of vaccination and the number of doses, it has been demonstrated that the protective responses extend for three or more years [17]. However, as pigs play important role in the JEV transmission cycle, therefore developing a new veterinary vaccine is considered as a useful strategy for cutting off the transmission route of JEV [18]. Internationally, an inactivated vaccine made from the mouse brain has been utilized for active vaccination for the past 50 years [19]. According to studies, Electroporation-mediated immunization significantly boosted immunogen expression at the injection site compared to intramuscular route and elicited an immunological response that was dose- and time-dependent [18]. To make JE vaccines more widely available, reasonably priced, and effective, researchers have been attempting to enhance currently available vaccinations. There have been efforts to create vaccinations that require fewer doses or that offer more durable protection, which can be especially helpful in environments with limited resources. Combination vaccinations that offer defense against a number of illnesses, including JE, have been researched. Combining the JE vaccine with other shots, including those for dengue or tick-borne encephalitis, can make vaccination schedules easier to follow and increase coverage. All visitors visiting nations where JE is an endemic disease should be counseled to take care to prevent mosquito bites in order to lower their risk of contracting JE and other vector-borne illnesses. However, JE vaccination is not suggested for travelers with very low-risk itineraries, such as shorter-term travel limited to metropolitan regions or outside of a well-defined JE virus transmission season [20]. Furthermore, many areas have stepped up their efforts to educate the public about JE, how it spreads, and what can be done to prevent it. To promote immunization, the usage of mosquito nets, and other protective practices, education campaigns have been carried out.

Treatment Strategies

One of the most dangerous infections in the world, Japanese encephalitis (JE), still lacks a cure or treatment recommendations. Although steroid treatment and antiviral drug ribavirin have been investigated for the treatment of JE but no significant results were achieved. A semi-synthetic tetracycline called minocycline has been demonstrated to be useful in both animal and human models of JE [10]. Minocycline penetrates the blood-brain barrier due to its lipophilic nature. The drug also inhibits the ribosome subunit 30s in bacteria [21]. Intravenous immunoglobulin (IVIG) with virus-specific neutralizing antibodies may be an effective treatment for JE, according to results from in-vitro trials and animal models [22]. However, numerous medications with activity against JEV have been identified through investigations in vitro and on animal models; these medications may be safe for use in people. Studies on pathogenesis and virology have elucidated the mechanisms by which these medications may function and have identified potential new treatments for Japanese encephalitis, frequently based on repurposing already-existing substances [23].

Global Health Initiative

Diverse organizations and programs focusing on early detection, immunization, research, and illness awareness are part of global efforts to combat Japanese encephalitis (JE). These programs are essential for easing the burden of JE in areas where it is endemic. In order to coordinate global efforts to combat JE, the WHO is crucial. It conducts surveillance, offers technical advice, and aids immunization campaigns in the nations impacted [24-27]. The vaccination of JE patients is a top priority in the WHO's Global Vaccine Action Plan. A public-private cooperation called Gavi makes vaccines, including those for Japanese encephalitis, more accessible to nations with lesser incomes. Gavi helps nations launch and maintain vaccination programs by providing financial and technical assistance. Furthermore, Governments and the United Nations Children's Fund (UNICEF) collaborate to guarantee the accessibility and fair distribution of JE vaccinations. To increase public knowledge of JE prevention, UNICEF supports immunization campaigns, develops health systems, and engages in advocacy work. Numerous academic institutions and research groups are investigating JE's epidemiology, genetics, and vaccine development. These initiatives aid in the improvement of preventative and treatment methods as well as the understanding of the disease. Various NGOs assist JE vaccine campaigns, create public awareness, and offer medical services in impacted communities in collaboration with governments and international organizations. To increase access to vaccines in areas where disease is endemic, pharmaceutical corporations work with international organizations.

Conclusion

Research, prevention, and treatment for Japanese encephalitis (JE) were all undergoing a number of improvements and advancements. Although there is no particular antiviral therapy for JE, research is still being done on prospective medicines and strategies to control the disease's symptoms, side effects and complications. The outcomes for severe patients are getting better thanks to developments in critical care and supportive therapies. The main goals of treatment for Japanese encephalitis (JE) are symptom management and supportive care. Since there is no specific antiviral medicine to treat JE, medical intervention focuses on symptom relief and giving the patient the best care possible. There has been continuous research into new approaches of controlling mosquitoes, such as using genetically altered mosquitoes or innovative insecticides. These methods seek to lower the mosquito population and, as a result, the spread of JE. Travelers are advised to take preventive measures, such as getting immunized, using anti-insect repellent, wearing protective clothes, and staying in air-conditioned or screened-in lodgings to avoid mosquito contact, when visiting endemic for JE areas. The need of vaccination is especially significant for those who live in or visit to high-risk areas.

References

1. Xu C, Zhang W, Pan Y, Wang G, Yin Q, et al. (2022) A Bibliometric Analysis of Global Research on Japanese Encephalitis From 1934 to 2020. Front Cell Infect Microbiol 12: 833701.

2. Poonsiri T, Wright GSA, Solomon T, Antonyuk SV (2019) Crystal Structure of the Japanese Encephalitis Virus Capsid Protein. Viruses 11(7): 623.

3. Kulkarni R, Sapkal GN, Kaushal H, Mourya DT (2018) Japanese Encephalitis: A Brief Review on Indian Perspectives. Open Virol J 12: 121-130.

4. Singh N, Abhinandan P, Khushboo B (2023) Antiviral Pathogenesis and Interventions: New Understandings and Developments. Acta Scientific Microbiology 6(8): 2-14.

5. Diwan T, Jain K, Singh N, Verma N, Jain V, et al. (2023) Biomedical Waste Management: An Assessment of Knowledge, Attitude and Practice among Healthcare Workers in Tertiary Care Hospital, Chhattisgarh. J Pure Appl Microbiol 17(1): 211-221.

6. Bhange K, Singh N (2023) Rising antibiotic resistance: growing concern. J Bacteriol Mycol Open Access 11(2): 110-112.

7. Sherwani N, Singh N, Verma N, Jain K, Neral A et al. (2021) Clinico-epidemiological profile of SARS-CoV-2 infection in individuals investigated at tertiary care hospital. J Med Sci Res 9(4): 187-191.

8. Sherwani N, Singh N, Neral A, Jaiswal J, Nagaria T, et al.

(2022) Placental Histopathology in COVID-19-Positive Mothers. J Microbiol Biotechnol 32(9): 1098-1102.

9. Kumar A, Sharma P, Shukla KK, Misra S, Nyati KK, et al. (2019) Japanese encephalitis virus: Associated immune response and recent progress in vaccine development. Microb Pathog 136: 103678.

10. Ajibowo AO, Ortiz JF, Alli A, Halan T, Kolawole OA, et al. (2021) Management of Japanese Encephalitis: A Current Update. Cureus 13(4): e14579.

11. Bandyopadhyay B, Bhattacharyya I, Adhikary S, Mondal S, Konar J, et al . (2013) Incidence of Japanese encephalitis among acute encephalitis syndrome cases in West Bengal, India. BioMed Res Int: 896749.

12. Kakoti G, Dutta P, Das RB, Borah J, Mahanta J, et al. (2013) Clinical profile and outcome of Japanese encephalitis in children admitted with acute encephalitis syndrome. BioMed Research International: 152656.

13. Singh N, Rai V (2012) Improved antimicrobial compound production by a new isolate Streptomyces hygroscopicus MTCC 4003 using Plackett-Burman design and response Surface methodology. Bioinformation 8(21): 1021-1025.

14. Sarkar A, Datta S, Pathak BK, Mukhopadhyay SK, Chatterjee S, et al. (2015) Japanese encephalitis associated acute encephalitis syndrome cases in West Bengal, India: A sero-molecular evaluation in relation to clinico-pathological spectrum. J Med Virol 87: 1258-1267.

15. Singh N, Rai V, Tripathi CK (2013) Purification and chemical characterization of antimicrobial compounds from a new soil isolate Streptomyces rimosus MTCC 10792. Prikl Biokhim Mikrobiol 49(5): 467-75.

16. Cao L, Fu S, Gao X, Li M, Cui S, et al. (2016) Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus. PLoS Negl Trop Dis 10(5): e0004686.

17. Hegde NR, Gore MM (2017) Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Human Vaccines & Immunotherapeutics 13(6): 1320-1337.

18. Sheng Z, Gao N, Cui X, Fan D, Chen H (2016) Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. Vaccine 34(47): 5751-5757.

19. Yun SI, Lee YM (2014) Japanese encephalitis: the virus and vaccines. Human Vaccines and Immunotherapeutics 10(2): 263-279.

20. Hills SL, Walter EB, Atmar RL, Fischer M (2019) Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 68(2):1-33.

21. Garrido MN, Zarzuelo A, Galvez J (2013) Minocycline: far beyond an antibiotic. British Journal of Pharmacology 169: 337-352.

22. Rayamajhi A, Nightingale S, Bhatta NK, Singh R, Kneen R et al. (2015) A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal PloS One 10(8): e0122608.

23. Turtle L, Solomon T (2018) Japanese encephalitis — the prospects for new treatments. Nat Rev Neurol 14: 298-313.

24. Plesner AM (2003) Allergic reactions to Japanese encephalitis vaccine. Immunol Allergy Clin N Am 23: 665-697.

25. Singh N, Sherwani N, Jaiswal J, Nagaria T, Neral A et al. (2022) Vertical Virus Transmission from SARS-CoV-2-positive Mothers to Neonates: An Experience at Tertiary Care Hospital. J Microbiol Infect Dis 12(1): 1-5.

26. Singh N, Jaiswal J, Sherwani N, Nagaria T, Khandwal O et al (2023) Maternal and Neonatal Outcomes Associated With COVID-19 Infection in Pregnant Mothers Admitted in Tertiary Care Hospital in Central State of India. Cureus 15(4): e38235.

27. Singh N, Rai V, Tripathi CKM (2012) Production and optimization of oxytetracycline by a new isolate Streptomyces rimosus using response surface methodology. Med Chem Res 21: 3140-3145.